On September 24th 2019, Ksilink Board of Directors appointed Professor Alain Beretz (on the left) as new Chairman of the Association, replacing Professor André Syrota (on the...
Ksilink acquires one high performance GPU/TPU cluster from locally-based 2CRSI company to implement deep learning approaches to its drug discovery programs for cardiovascular and...
Ksilink initiates 2 new drug discovery programs on Muscular Dystrophy-1 (DM1) and Autism Spectrum Disorders (ASD) with its strategic partner I-Stem. Click here to download the...
Together with Anagenesis Biotechnologies, Ksilink reachs first exit point in the field of Duchenne Muscular Disease. A major industrial Venture Fund invests into  Anagenesis with...
Ksilink teams up with the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg to develop drugs to treat Parkinson’s disease. Together they will...
On June 8th 2016, Sanofi and Ksilink announced that they have entered into a research collaboration aiming to accelerate the discovery of next-generation therapies addressing...
On February 2nd 2016, Ksilink and Anagenesis Biotechnologies announce a collaborative research agreement to apply stem-cell derived disease models of Duchenne Muscular Dystrophy...
On September 8th 2015, Ksilink, the Institute of Reconstructive Neurobiology, University of Bonn and the Life & Brain GmbH announced that they have forged an alliance to...
